Bioavailability of Hydroxytyrosol From Olive Watery Extract Supplements

Biological Availability Clinical Trial

Official title:

Bioavailability of Hydroxytyrosol From Two Olive Watery Extract Supplements and Their Effects on Lipid Peroxidation

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04876261
• Other study ID #: IK03-2020
• Status: Completed
• Phase: N/A
• Start date: May 10, 2021
• Est. completion date: July 2, 2021

Study information

• Verified date: July 2021
• Source: Daacro
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this cross-over study is to assess the bioavailability of hydroxytyrosol in healthy males after the intake of two olive watery extract supplements and one olive oil. Blood and urine samples will be collected before and after intake of the investigational products. Sample will be analysed regarding the level of hydroxytyrosol and preventing lipid peroxidation.

Description:

Background: Hydroxytyrosol is a phenolic phytochemical naturally occurring in olives with potential antioxidant, anti-inflammatory, and health benefits mainly related with cardiovascular diseases [for review see Covas et al., 2015]. OliPhenolia® bitter and OliPhenolia® are two food supplements resulting from the liquid by-product generated during olive oil production, that are rich in olive polyphenols, mainly hydroxytyrosol. Hydroxytyrosol and its derivatives (tyrosol and oleuropein) are present in higher levels in the watery extracts from olives when compared with the oil fraction. Most studies on hydroxytyrosol bioavailability have been performed by consuming it with olive oil or as a highly purified molecule. In a study by D'Angelo and collaborators [D'Angelo et al, 2001] it was shown that hydroxytyrosol can be rapidly absorbed from the blood and distributed in the human body, metabolized and eliminated rapidly in urine mainly as a glucuronide. It has been estimated that the absorption process depends on the composition of the food matrix through which hydroxytyrosol is administered [Visioli et al, 2003], when consumed together with fats (e.g. olive oil) it is absorbed in a greater extent. By being a water-soluble molecule, hydroxytyrosol is only slightly soluble in fats, therefore naturally present in significantly higher concentrations in the olive fruit aqueous fractions than in the olive oil. Overall, the human studies support the need to evaluate the bioavailability of hydroxytyrosol following its administration as a major component of the two aqueous food supplements, OliPhenolia® and OliPhenolia® bitter. Study Procedure: After detailed information and signed informed consent all males meeting the inclusion and exclusion criteria will be included into the study. During their study participation, participants are not allowed to consume any products with or made from olives or olive oil as well as alcohol and supplements with hydroxytyrosol, vitamins, minerals and antioxidants. Products high in polyphenols and antioxidants may only be consumed in moderate amounts. Three days prior to and at each intervention day, volunteers will be requested to avoid moderate or intense physical activity. After a run-in period, participants will return in a fasted state to the site for the first intervention visit. Volunteers will be asked to empty their bladder at home 2h before IP intake. After arriving at the site, a baseline blood and urine sample (-5 min) will be collected and the participants receive according to the individual allocation determining the sequence of the IP intake either one of the olive watery extract supplements (OliPhenolia® bitter or OliPhenolia®) or the olive oil first. Further blood and urine samples will follow (+30 min, +60 min, +90 min, +120 min, +240 min, +12 h). Vital signs and AEs will be checked throughout the intervention visit. Participants will receive several snacks and water during their visit. After a one-week washout phase each, participants will return to their second and third intervention visit. The same procedures as on intervention visit 1 will take place except the IP intake will vary according to the individual allocation. At the end of the third intervention visit, participants will receive a study compensation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: July 2, 2021
• Est. primary completion date: July 2, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 21 Years to 50 Years

Eligibility

Inclusion Criteria:

• Self-reported healthy men aged 21-50,
• subject has an adequate understanding of the study and signs the informed consent to participate in the study,
• willingness to follow dietary and physical activity restrictions during study participation,
• body mass index range: >18.5 and <29.9 kg/m2.

Exclusion Criteria:

• Any known allergies to IPs (olives and their derivates),
• any acute and chronic diseases (e.g. diagnosis of diabetes mellitus, hypertension, dyslipidemia or other cardiometabolic disorders, diagnosed hepatic, renal, or cardiovascular disease),
• any kind of eating disorders,
• not fluent in German,
• any previous (last 14 days prior to screening) and any ongoing pharmacological therapy (e.g. any medication, vaccination, infusion),
• any intake of nutritional supplements,
• any known addiction to drugs and/or alcohol,
• smoker,
• Investigator or physician doubts truthfulness of self-reported health information.

Related Conditions & MeSH terms

• Biological Availability

Intervention

Dietary Supplement:
• Oliphenolia® bitter
ingredients: concentrated watery extract of olives 94%, lemon juice 6% 35 mg hydroxytyrosol, 0,24 mg Oleuropein
• Oliphenolia®
ingredients: grape juice concentrate 70%, concentrated watery extract of olives 30% 38 mg hydroxytyrosol, 0,28 mg Oleuropein
• La Vialla Extra Virgin Olive Oil containing 5 mg hydroxytyrosol
extra virgin olive oil 5 mg hydroxytyrosol

Locations

Country	Name	City	State
Germany	daacro GmbH & Co. KG	Trier	Rhineland-Palatinate

Sponsors (4)

Lead Sponsor	Collaborator
Daacro	Fattoria La Vialla di Gianni, Antonio e Bandino Lo Franco Soc. Agr. Sempl., Institut Kurz GmbH, ISTITUTO KURZ ITALIA S.R.L.

Country where clinical trial is conducted

Germany, 

References & Publications (12)

Caruso D, Visioli F, Patelli R, Galli C, Galli G. Urinary excretion of olive oil phenols and their metabolites in humans. Metabolism. 2001 Dec;50(12):1426-8. — View Citation

Covas MI, de la Torre R, Fitó M. Virgin olive oil: a key food for cardiovascular risk protection. Br J Nutr. 2015 Apr;113 Suppl 2:S19-28. doi: 10.1017/S0007114515000136. Review. — View Citation

Covas MI, Nyyssönen K, Poulsen HE, Kaikkonen J, Zunft HJ, Kiesewetter H, Gaddi A, de la Torre R, Mursu J, Bäumler H, Nascetti S, Salonen JT, Fitó M, Virtanen J, Marrugat J; EUROLIVE Study Group. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med. 2006 Sep 5;145(5):333-41. — View Citation

D'Angelo S, Manna C, Migliardi V, Mazzoni O, Morrica P, Capasso G, Pontoni G, Galletti P, Zappia V. Pharmacokinetics and metabolism of hydroxytyrosol, a natural antioxidant from olive oil. Drug Metab Dispos. 2001 Nov;29(11):1492-8. — View Citation

de Bock M, Thorstensen EB, Derraik JG, Henderson HV, Hofman PL, Cutfield WS. Human absorption and metabolism of oleuropein and hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract. Mol Nutr Food Res. 2013 Nov;57(11):2079-85. doi: 10.1002/mnfr.201200795. Epub 2013 Jun 14. — View Citation

Hohmann CD, Cramer H, Michalsen A, Kessler C, Steckhan N, Choi K, Dobos G. Effects of high phenolic olive oil on cardiovascular risk factors: A systematic review and meta-analysis. Phytomedicine. 2015 Jun 1;22(6):631-40. doi: 10.1016/j.phymed.2015.03.019. Epub 2015 Apr 20. Review. — View Citation

Karkovic Markovic A, Toric J, Barbaric M, Jakobušic Brala C. Hydroxytyrosol, Tyrosol and Derivatives and Their Potential Effects on Human Health. Molecules. 2019 May 24;24(10). pii: E2001. doi: 10.3390/molecules24102001. Review. — View Citation

Mateos R, Martínez-López S, Baeza Arévalo G, Amigo-Benavent M, Sarriá B, Bravo-Clemente L. Hydroxytyrosol in functional hydroxytyrosol-enriched biscuits is highly bioavailable and decreases oxidised low density lipoprotein levels in humans. Food Chem. 2016 Aug 15;205:248-56. doi: 10.1016/j.foodchem.2016.03.011. Epub 2016 Mar 4. — View Citation

Miró-Casas E, Covas MI, Fitó M, Farré-Albadalejo M, Marrugat J, de la Torre R. Tyrosol and hydroxytyrosol are absorbed from moderate and sustained doses of virgin olive oil in humans. Eur J Clin Nutr. 2003 Jan;57(1):186-90. — View Citation

Suárez M, Valls RM, Romero MP, Macià A, Fernández S, Giralt M, Solà R, Motilva MJ. Bioavailability of phenols from a phenol-enriched olive oil. Br J Nutr. 2011 Dec;106(11):1691-701. doi: 10.1017/S0007114511002200. Epub 2011 Jun 21. — View Citation

Visioli F, Galli C, Bornet F, Mattei A, Patelli R, Galli G, Caruso D. Olive oil phenolics are dose-dependently absorbed in humans. FEBS Lett. 2000 Feb 25;468(2-3):159-60. — View Citation

Visioli F, Galli C, Grande S, Colonnelli K, Patelli C, Galli G, Caruso D. Hydroxytyrosol excretion differs between rats and humans and depends on the vehicle of administration. J Nutr. 2003 Aug;133(8):2612-5. — View Citation

* Note: There are 12 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bioavailability of hydroxytyrosol in urine	The primary objective is the bioavailability of hydroxytyrosol and its derivatives from both food supplements (OliPhenolia® bitter and OliPhenolia®) in urine when compared to extra virgin olive oil.	-2 hrs to IP intake, 0 to 30 min, 30 to 60 min, 60 to 90 min, 90 to 120 min, 120 to 240 min and +4h to +12h
Primary	Bioavailability of hydroxytyrosol in blood	The primary objective is the bioavailability of hydroxytyrosol and its derivatives from both food supplements (OliPhenolia® bitter and OliPhenolia®) in urine when compared to extra virgin olive oil.	5 min. before IP intake, 30, 60, 90, 120, 240 min and 12 h
Secondary	Oxidative damages to lipids in blood	The secondary outcome is the measurement of the oxidized LDL(low-density lipoprotein) in blood	5 min. before IP intake, 30, 60, 90, 120, 240 min and 12 h
Secondary	changes in F2alpha-isoprostanes in urine	The secondary outcome is the measurement of changes in F2alpha-isoprostanes in urine.	-2 hrs to IP intake, 0 to 30 min, 30 to 60 min, 60 to 90 min, 90 to 120 min, 120 to 240 min and +4h to +12h